If you want to know the importance of the work getting developed by PTX and TF this article sponsored by thermo fisher is a good read.
"It was estimated that 450,000 cancer patients were eligible for this therapeutic, but in 2021, only 4,000 commercial doses of CAR T-cell therapy were manufactured. Unfortunately, it’s estimated that 20% of patients eligible for an FDA-approved cell therapy pass away before receiving their treatment, according to the MD Anderson Cancer Center."
It shows the importance of developing a scalable product. current CAR T therapies are mostly academic products they are not designed to be commercially manufactured to treat larger population hopefully in due time prescient can shed some more light on TF collaboration and be positioned to service this need.
PTX Price at posting:
5.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)